Gernicke and Gleevec both refer to imatinib mesylate, and the difference between the two is in terms of origin, clinical time, and price.
1. Imatinib mesylate, used in the treatment of chronic granulocytic leukemia, Gnicor is domestic imatinib, Gleevec is foreign imported imatinib.
2. Clinical time is different: Gleevec has a relatively long clinical data, is a first-line treatment drugs, Gernicke only listed in 2013 or so, the relative lack of clinical data.
3. Price is different: the price of Ganco is relatively cheaper, Gleevec is more expensive.
But the two from the efficacy of comparison, the difference is not great, applicable to chronic granulocytic leukemia in the chronic phase, accelerated phase, acute phase, may produce gastrointestinal reactions, skin rashes, muscle aches and pains and other adverse reactions, for the class of drugs will be the active substance or any kind of excipient allergic to the person is prohibited.
Specifically need to be under the guidance of a professional doctor in conjunction with their own situation of the correct use.